Cargando…

Safety of PPAR Agonists

Detalles Bibliográficos
Autor principal:	Home, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2011
Materias:	Diabetes Treatments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632164/ https://www.ncbi.nlm.nih.gov/pubmed/21525458 http://dx.doi.org/10.2337/dc11-s233

Ejemplares similares

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability
por: Garber, Alan J.
Publicado: (2011)

Glycemic Control Impact on Body Weight Potential to Reduce Cardiovascular Risk: Glucagon-like peptide 1 agonists
por: Sesti, Giorgio
Publicado: (2011)

Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
por: DeFronzo, Ralph A., et al.
Publicado: (2011)

Long-Term Benefits From Lifestyle Interventions for Type 2 Diabetes Prevention: Time to expand the efforts
por: Tuomilehto, Jaakko, et al.
Publicado: (2011)

Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes
por: Bolli, Geremia B., et al.
Publicado: (2011)

Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes
por: Lebovitz, Harold E.
Publicado: (2011)

Multidrug Treatment of Type 2 Diabetes: A challenge for compliance
por: Miccoli, Roberto, et al.
Publicado: (2011)

Glucokinase Activators for Diabetes Therapy: May 2010 status report
por: Matschinsky, Franz M., et al.
Publicado: (2011)

Role of Bile Acid Sequestrants in the Treatment of Type 2 Diabetes
por: Handelsman, Yehuda
Publicado: (2011)

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
por: Holst, Jens J., et al.
Publicado: (2011)

Incretin Effects on β-Cell Function, Replication, and Mass: The human perspective
por: Garber, Alan J.
Publicado: (2011)

Therapy in the Early Stage: Incretins
por: Cernea, Simona, et al.
Publicado: (2011)

DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors
por: Dicker, Dror
Publicado: (2011)

An Outline of the Allen Method
Publicado: (1919)

Waiting for JAK inhibitor safety data
por: Kragstrup, Tue Wenzel, et al.
Publicado: (2022)

Should A1C Targets Be Individualized for All People With Diabetes?: Arguments for and against
por: Teoh, Hwee, et al.
Publicado: (2011)

Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial
por: Cohen-Solal, Alain, et al.
Publicado: (2009)

Efficacy and safety of emapalumab in macrophage activation syndrome
por: De Benedetti, Fabrizio, et al.
Publicado: (2023)

Insulin Therapy and Cancer
por: Home, Philip
Publicado: (2013)

Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews
por: Rodriguez-García, Sebastián Cruz, et al.
Publicado: (2021)

Comprehensive analysis of PPARγ agonist activities of stereo-, regio-, and enantio-isomers of hydroxyoctadecadienoic acids
por: Umeno, Aya, et al.
Publicado: (2020)

Efficacy and safety of low‐dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double‐blind, parallel, phase II trial
por: Sung, Ki‐Chul, et al.
Publicado: (2022)

Rationale and design of a multicenter randomized study comparing the efficacy and safety of esaxerenone versus trichlormethiazide in patients with uncontrolled essential hypertension: EXCITE‐HT study
por: Kario, Kazuomi, et al.
Publicado: (2023)

Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials
por: Curtis, Jeffrey R, et al.
Publicado: (2019)

Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo‐controlled trial
por: Anker, Stefan D., et al.
Publicado: (2015)

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
por: Mease, Philip, et al.
Publicado: (2020)

GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015
por: Gallwitz, Baptist
Publicado: (2015)

Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
por: Berman, Casey, et al.
Publicado: (2023)

Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer’s Disease
por: Colin, Ides M, et al.
Publicado: (2023)

Intervention against Excessive Alcohol Consumption in Primary Health Care: A Survey of GPs' Attitudes and Practices in England 10 Years On
por: Wilson, Graeme B., et al.
Publicado: (2011)

Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial
por: Düngen, Hans-Dirk, et al.
Publicado: (2011)

Early Treatment for Women with Alcohol Addiction (EWA) Reduces Mortality: A Randomized Controlled Trial with Long-Term Register Follow-up
por: Gjestad, Rolf, et al.
Publicado: (2011)

Development of a Psychologically Enhanced Interactive Online Intervention for Hazardous Drinking
por: Linke, Stuart, et al.
Publicado: (2008)

A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction
por: Parthasarathy, Hari K., et al.
Publicado: (2009)

Twelve-Month Follow-up Results from a Randomized Controlled Trial of a Brief Personalized Feedback Intervention for Problem Drinkers
por: Cunningham, John A., et al.
Publicado: (2010)

Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial
por: Siminiak, Tomasz, et al.
Publicado: (2012)

Awareness and Treatment of Alcohol Dependence in Japan: Results from Internet-Based Surveys in Persons, Family, Physicians and Society
por: Taguchi, Yurie, et al.
Publicado: (2014)

The Alcohol Improvement Programme: Evaluation of an Initiative to Address Alcohol-Related Health Harm in England
por: Thom, Betsy, et al.
Publicado: (2013)

Efficacy of As-Needed Nalmefene in Alcohol-Dependent Patients with at Least a High Drinking Risk Level: Results from a Subgroup Analysis of Two Randomized Controlled 6-Month Studies
por: van den Brink, Wim, et al.
Publicado: (2013)

Nine-year follow-up of local implantation of autologous skeletal myoblasts in a patient with coronary heart disease
por: Zhang, Dingguo, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_12iu8fjrjh0ebeq60091t0i7il